Skip to: Content
Skip to: Site Navigation
Skip to: Search
WEDNESDAY, NOVEMBER 25, 2009
| Subscribe to Newser's RSS feeds RSS | Follow Newser on Twitter Twitter

NEWS ABOUT: Roche Holding

Roche Holding stories: 4 news summaries

Roche Makes Genentech Takeover Bid

Swiss pharma bids $43.7B for remaining shares of biotech firm

Jul 21, 08 6:55 AM CDT
(Newser) - Swiss pharmaceutical company Roche today offered $43.7 billion for the outstanding shares of Genentech, the San Francisco-based biotech firm in which Roche already owns a 55.9% stake, the Wall Street Journal reports. The $89-a-share offer is the latest in a series of big pharma companies, whose new drug... More »

MORE ABOUT:
mergers and acquisitions • takeover • Genentech • Roche Holding • Pharamceuticals

Cancer Drug Sales Push Genentech Profits Up 12%

But analysts say Avastin sales slowing

Apr 11, 08 8:28 AM CDT
(Newser) - Biotech firm Genentech said sales of its blockbuster cancer drug Avastin fueled a first-quarter profit increase of 12%, reports the Wall Street Journal, but the $600 million in sales was below analysts’ projected $622 million, causing some to grumble the drug may have reached a sales plateau. Genentech stock... More »

MORE ABOUT:
FDA • breast cancer • corporate earnings • Genentech • Roche Holding • Avastin

FDA May Add Warnings
to Flu Meds

Hallucinations, other side effects seen with Tamiflu, Relenza

Nov 23, 07 4:12 PM CST
(Newser) - The FDA may change the labels of flu medications Tamiflu and Relenza to warn of serious side effects such as hallucinations, the Wall Street Journal reports. More than 700 so-called neuropsychiatric events—for example, children trying to "flee" by jumping through windows—and 16 deaths may be related to... More »

MORE ABOUT:
Roche Holding • influenza • side effects • neuropsychiatric events • Tamiflu • Relenza

Biotech Giant Slashes Jobs

World biggest biotech cuts 2,600 jobs in $2B restructuring

Aug 16, 07 1:34 AM CDT
(Newser) - Biotech giant Amgen is slashing spending by $1.9 billion by cutting up to 14 percent of its workforce— 2,600 jobs—and closing some production facilities. The restructuring was triggered by plummeting sales of the company's anemia drug Aranesp. The shake up demonstrates that biotech operations are not immune... More »

MORE ABOUT:
biotechnology • Amgen • Aranesp • Genentech • restructuring • Cera • Roche Holding • Kevin Sharer

4 Stories


from our news partners